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A wide range of neurodegenerative diseases (NDs), including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and
prion diseases, share common mechanisms such as neuronal loss, apoptosis, mitochondrial dysfunction, oxidative stress, and
inﬂammation. Intervention strategies using plant-derived bioactive compounds have been oﬀered as a form of treatment for
these debilitating conditions, as there are currently no remedies to prevent, reverse, or halt the progression of neuronal loss.
Rutin, a glycoside of the ﬂavonoid quercetin, is found in many plants and fruits, especially buckwheat, apricots, cherries, grapes,
grapefruit, plums, and oranges. Pharmacological studies have reported the beneﬁcial eﬀects of rutin in many disease conditions,
and its therapeutic potential in several models of NDs has created considerable excitement. Here, we have summarized the
current knowledge on the neuroprotective mechanisms of rutin in various experimental models of NDs. The mechanisms of
action reviewed in this article include reduction of proinﬂammatory cytokines, improved antioxidant enzyme activities,
activation of the mitogen-activated protein kinase cascade, downregulation of mRNA expression of PD-linked and proapoptotic
genes, upregulation of the ion transport and antiapoptotic genes, and restoration of the activities of mitochondrial complex
enzymes. Taken together, these ﬁndings suggest that rutin may be a promising neuroprotective compound for the
treatment of NDs.
1. Introduction
Neurodegenerative diseases (NDs) are regarded as an age-
related group of chronic and untreatable conditions which
constitutes a major threat to human health [1]. They are
becoming increasingly prevalent, due to a signiﬁcant increase
in the size of elderly populations worldwide [2]. NDs repre-
sent the fourth highest source of disease burden in high-
income countries, in terms of economic cost for society [3].
NDs are characterized by the gradual and progressive loss
of neurons and diverse clinical features such as memory
and cognitive impairments and others aﬀecting a person’s
ability to move, speak, and breathe [4–6]. Some overlapping
pathways recognized in the pathogenicity of NDs include free
radical formation and oxidative stress, protein misfolding
and aggregation, metal dyshomeostasis, phosphorylation
impairment, and mitochondrial dysfunction [7] (Figure 1).
Oxidative stress has been shown by many studies to be
a crucial player in the development and progression of
NDs [8]. Oxidative stress is deﬁned as the disturbance in
balance between prooxidant and antioxidant levels and
results from an imbalance between the production of reac-
tive oxygen species (ROS) and the biological system’s abil-
ity to detoxify the reactive intermediates [8]. ROS play
important roles in mediating cellular activities [9, 10];
however, due to their reactivity, high amounts of ROS
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can cause cell death or oxidative stress [11]. While it is
still unclear whether ROS is the triggering factor for
NDs, they are likely to aggravate disease progression
through oxidative damage and eﬀects on mitochondria.
In view of the important roles of oxidative stress in NDs,
the manipulation of ROS levels may be an encouraging treat-
ment option to delay neurodegeneration and attenuate asso-
ciated symptoms. Presently, there is no potent treatment for
NDs and the available drugs are mainly focused on symp-
toms though with many adverse eﬀects and limited ability
to prevent disease progression [12].
Accordingly, medicinal plants such as Hypericum perfor-
atum possessing antioxidant properties have been studied for
their potential to attenuate neurodegenerative symptoms
[13–16]. For instance, previous reports show that extracts
of H. perforatum signiﬁcantly attenuated oxidative stress by
reducing lipid peroxidation [17], reducing oxidation of the
mitochondrial lipid membrane [18], preserving the activities
of antioxidant enzymes [19], and consequently preventing
neurotoxicity in experimental models of NDs. As a result of
these ﬁndings amongst others, Sánchez-Reus et al. proposed
standardized extracts of H. perforatum as a possible treat-
ment for elderly patients showing signs of NDs associated
with elevated oxidative stress [19]. Although reports show
that treatments involving H. perforatum are generally safe,
minor adverse eﬀects have been reported; they include dizzi-
ness, allergic reactions, restlessness, gastrointestinal symp-
toms, dryness of the mouth, and lethargy [20–22].
Similarly, there is currently an increase in the usage of
natural compounds/products as potential neuroprotective
agents. Examples include, curcumin, bilobalide, chitosan,
and apigenin, all known to have potent protective eﬀects on
neurons [23–28]. Recently, bioﬂavonoids have found use in
the healthcare system owing to their wide range of biological
activities, low cost, and signiﬁcantly high safety margins [29].
Rutin (3,3′,4′,5,7-pentahydroxyﬂavone-3-rhamnoglucoside,
Figure 2) also called sophorin, rutoside, and quercetin-3-
rutinoside is a polyphenolic bioﬂavonoid, largely extracted
from natural sources such as oranges, lemons, grapes, limes,
berries, and peaches [30, 31]. Rutin is a vital nutritional com-
ponent of plants [32] and its name originates from the plant
Ruta graveolens, which also contains rutin [33]. Chemically,
it is a glycoside comprising of ﬂavonol aglycone quercetin
along with disaccharide rutinose [33]. Some studies suggest
that rutin has a potential protective role in NDs due to its
beneﬁcial eﬀects as a potent antioxidant [34, 35]. Hence, this
review presents an outline of the scientiﬁc literature regard-
ing the potential neuroprotective role of rutin in NDs.
1.1. Oxidative Stress and Reactive Oxygen Species. Oxygen is
essential for all multicellular life but in excess, it is potentially
hazardous. ROS is formed when cells exposed to oxygen con-
tinuously generate oxygen free radicals. Endogenous free
radicals are generated from inﬂammation, mental stress,
immune cell activation, excessive exercise, infection, ische-
mia, cancer, and aging while exogenous free radicals are pro-
duced from air and water pollution, radiation, alcohol,
cooking (smoked meat, used oil, and fat), heavy or transition
metals, cigarette smoke, and industrial solvents [36–38]. The
main source of endogenous ROS production is the mito-
chondria but it can also occur in other organelles [39]. ROS
include free radicals (superoxide, •O−2), hydroxyl radical
(•OH), or nonradicals (hydrogen peroxide, H2O2).
•O−2 is
proposed to play a crucial role in ROS production and •OH
is recognized as the most reactive ROS that are primarily lia-
ble for the toxic eﬀects of ROS [40].
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Figure 1: Various processes shown to be dysregulated in neurodegenerative disorders.
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Cellular levels of ROS may be decreased through the
defence mechanisms of small-molecule antioxidants and
antioxidant enzymes [41]. •O−2 is reduced by superoxide dis-
mutases (SOD) into the more stable form of H2O2. H2O2
may produce highly reactive hydroxyl radicals •OH and can
be reduced to H2O and O2 by catalase (CAT), glutathione
peroxidase (GPx), and other peroxidases [42, 43]. The cellu-
lar antioxidant glutathione (GSH) is involved in two types of
reactions. First of all, in its reduced form, GSH nonenzyma-
tically reacts with •O−2 and
•OH for the elimination of ROS
[41, 44]. Next, GSH serves as the electron contributor for
the reduction of peroxides in the GPx reaction [45]. When
GSH reacts with ROS, it is oxidized (GSSG) and produces
glutathione disulﬁde (the last product of GPx reactions).
GSH can be further restored from glutathione disulﬁde by
the reaction with glutathione reductase through a transfer
of electrons from NADPH to glutathione disulﬁde [46].
Numerous studies have stated that GSH is involved in
impeding apoptotic cell death and DNA damage in cells fol-
lowing oxidative stress [47, 48]. Hence, cellular antioxidants
and antioxidant enzymes work together to prevent the accu-
mulation of damaging ROS in the cell. Dysregulation of their
functions is an indication of altered oxidative states, which
may contribute to cell death.
The harmful eﬀects of ROS include damage of DNA or
RNA, oxidation of amino acids in proteins, oxidative deac-
tivation of particular enzymes by oxidation of cofactors,
and oxidations of polyunsaturated fatty acids in lipids
(lipid peroxidation). The uninterrupted attack of protein
by ROS forms protein carbonyls and nitrites, such that
monitoring of their levels provides an additional measure
of the eﬀect of oxidative stress [49]. Lipid peroxidation
results in the generation of lipid peroxidation products
such as malondialdehyde (MDA) and thiobarbituric acid
reactive substances (TBARS) [50]. Assay of TBARS mea-
sures MDA present in the sample and MDA generated
from lipid hydroperoxides. An increase in free radicals is
directly proportional to overproduction of MDA and is
therefore a commonly used marker of oxidative stress
and antioxidant status [50].
2. Link between Oxidative Stress and
Neurodegenerative Disorders
The pathogenesis of NDs is a complex interplay between
genetic and nongenetic factors [51]. Generally, nongenetic/
sporadic forms represent the majority of these cases. There
are a number of NDs, but for the purposes of this review,
we will focus on Alzheimer’s disease (AD), Parkinson’s
disease (PD), Huntington’s disease (HD), and human prion
diseases (PrDs) [1, 12].
AD is the most common ND and it primarily aﬀects mid-
dle- to old-aged individuals, nearly one in four individuals
over the age of 85 [52]. AD has various etiological factors
including genetic and environmental factors [52, 53]. It is
characterized by neuronal loss and atrophy in the neocortex,
hippocampus, amygdala, and basal forebrain [54, 55]. Its
pathophysiological hallmarks include depositions in the
forms of senile plaques, extracellular β-amyloid (Aβ) pro-
tein, and intracellular deposits of the microtubule-linked
protein tau as neuroﬁbrillary tangles in the AD brains leading
to dementia [56].
A common pathological feature in AD is the oxidation of
nucleic acids, proteins, and lipids in neurons [57]. ROS inter-
acts with polyunsaturated fatty acids in the neurons, leading
to high levels of lipid peroxidation [58]. Increased levels of
oxidative stress biomarkers (carbonyls, MDA, and 3-nitro-
tyrosine) in the blood [59, 60] and changes in the activities
of antioxidant enzymes (SOD and CAT) reﬂect oxidative
stress in the brain [61, 62].
The underlying mechanisms (Figure 3) proposed for the
initiation of oxidative stress in AD include Aβ accumulation
[63, 64], hyperphosphorylated tau [65, 66], inﬂammation
[67, 68], mitochondrial dysfunction [64, 69], and metal accu-
mulation [70, 71].
To date, there is no treatment that can cure AD, but there
are available symptomatic drug treatments consisting mostly
of cholinesterase inhibitors such as donepezil, rivastigmine,
and galantamine [72]. Others include memantine [73, 74],
a N-methyl-D-aspartate receptor antagonist approved by
the US Food and Drug Administration (FDA), and a combi-
nation of memantine with donepezil [75].
PD is characterized by chronic degeneration of dopami-
nergic neurons in the substantia nigra pars compacta of the
midbrain [76]. This in turn results in the depletion of dopa-
mine neurotransmitter production, which leads to motor
deﬁcits such as symptomatic rigidity, bradykinesia, postural
instability, and resting tremor [77]. The cause of dopaminer-
gic neuronal cell death in PD remains unidentiﬁed, but sev-
eral factors such as oxidative stress may contribute to this
degeneration and have been closely linked to other sections
of neurodegenerative processes, such as α-synuclein, inﬂam-
mation, and cell death [78–81].
Oxidative stress is believed to be a fundamental mecha-
nism leading to cellular dysfunction in both idiopathic and
familial forms of PD. An increase in protein oxidation has
been detected in the substantia nigra of PD patients com-
pared to healthy individuals [82]. Accordingly, the substantia
nigra of PD patients reveals decreased levels of GSH and
higher levels of oxidized proteins, DNA, and lipids [83, 84].
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Figure 2: Diagram showing the chemical structure of rutin.
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The accumulation of lipid peroxidation by-products has been
reported in the serum and cerebral spinal ﬂuid of PD patients
while higher levels of MDA and TBARS have been reported
in the substantia nigra and stratum of PD brains [85–87].
Various mechanisms for the generation of ROS in PD
includemitochondrial dysfunction, metabolism of dopamine,
iron, aging, calcium, andneuroinﬂammation [88]. PDcausing
genes such as SNCA, DJ-1, LRRK2, PINK1, and PARK2 also
aﬀect in complex ways leading to aggravation of ROS produc-
tion and vulnerability to oxidative stress [88]. In addition,
homeostatic processes such as mitophagy and the ubiquitin-
proteasome system are aﬀected by oxidative stress [88]. The
interaction amongst these numerousmechanisms are thought
to contribute to neurodegeneration in PD (Figure 4).
The primary treatment for symptomatic patients and the
most eﬀective pharmacologic agent for PD is levodopa [89,
90]. It is reported that levodopa is mostly eﬀective at control-
ling rigidity and bradykinesia [89]; however, postural reﬂex,
gait disturbance, and speech are less likely to respond. Levo-
dopa is combined with carbidopa, because carbidopa blocks
dopa decarboxylase thereby preventing peripheral conver-
sion of levodopa to dopamine. Additionally, its combination
with levodopa reduces the peripheral adverse eﬀects of dopa-
mine (e.g., nausea and hypotension) and increases cerebral
levodopa bioavailability. Treatment with monoamine
oxidase-B (MAO-B) inhibitors, amantadine (Symmetrel),
or anticholinergics may modestly improve mild symptoms;
nevertheless, most patients need a dopamine agonist or levo-
dopa [91]. Furthermore, advances in brain imaging and neu-
rosurgical techniques has highlighted surgical treatment for
this disorder. In an evidence-based review, it is reported that
deep brain stimulation of the subthalamic nucleus eﬀectively
improves motor function and reduces dyskinesia and motor
ﬂuctuations [90, 92].
HD is characterized by motor, cognitive, and behavioral
dysfunction [93] and demonstrates an autosomal dominant
mode of inheritance [94]. It is characterized by a remarkable
speciﬁcity of neuronal loss and the regions most aﬀected are
the striatum, where there is usually 50–60% loss of cross-
sectional area from the caudate nucleus and the putamen in
advanced stages of the disease [95]. HD is linked with a triad
of symptoms which includes cognitive deterioration, move-
ment disorders, and psychiatric disturbances [95]. These
signs begin subtly, most frequently between the ages of 35
to 50, but the age of onset can diﬀer from early childhood
until old age. The disease is relentlessly progressive and is
deemed to be fatal 15–20 years after the onset of symptoms
[95]. Classical features of HD are disturbances of motor
function which include chorea (unintentional brief
movements that tends to ﬂow between body regions) and
progressive deﬁciency of coordination of voluntary
movements [95–98].
Convincing data supports a critical role for oxidative
stress in the pathogenesis of HD [99–101] (Figure 5). Mutant
huntingtin proteins (MTPs) serve as the source of ROS,
owing to a substantial amount of oxidized proteins in
partially puriﬁed MTP aggregates [99]. It is proposed that
elevated oxidative stress is a major mechanism in the late
stages of HD pathogenesis. [100]. Another mechanism
involved in ROS-mediated HD pathogenesis is the impair-
ment of the electron transport chain and mitochondrial
dysfunction [102, 103]. Defects in oxidative phosphoryla-
tion have been detected in the brain tissues of HD patients
[104], and enhanced lipid peroxidation accompanied by
reduced GSH content has been reported in patients with
severe symptoms of HD [101, 105, 106]. Substantial oxida-
tive DNA damage has also been reported in HD mouse
models [107, 108].
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Figure 3: Schematic diagram showing the role of oxidative stress (OS) in Alzheimer’s disease.
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There are no existing treatments to alter the course of
HD, but symptomatic therapies and education are eﬀective
tools used by clinicians in addressing patients and families
aﬀected by HD. Several drugs and surgical procedures have
been assessed in HD for their eﬀectiveness in subduing cho-
rea. These include dopamine-depleting agents, agonists and
antagonists, deep brain stimulation, benzodiazepines, fetal
cell transplantation, acetylcholinesterase inhibitors, gluta-
mate antagonists, antiseizure prescriptions, lithium, and
cannabinoids [94, 109, 110]. Tetrabenazine is the only FDA-
approved drug for HD designated for the treatment of chorea
linked with HD [111, 112]. Other promising drugs shown in
controlled trials to considerably lessen chorea in HD patients
include amantadine [113], olanzapine [114, 115], quetiapine
[116, 117], and aripiprazole [118, 119].
PrDs are related to a variety of clinical presentations and
have attracted vast research awareness for many years not
only due to their distinctive composition and properties but
also because of their eﬀect on public health [120–122]. Exam-
ples of PrDs include Gerstmann Sträussler-Scheinker
syndrome, Creutzfeldt-Jakob disease (CJD), kuru, and fatal
familial insomnia while animal PrDs include scrapie and
bovine spongiform encephalopathy [123].
According to the “protein-only” hypothesis [124, 125],
host-encoded cellular prion protein (PrPC) is converted to
a diﬀerent structural isoform which is known as PrPSc
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Figure 4: Schematic diagram showing the role of oxidative stress in Parkinson’s disease.
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Figure 5: Schematic diagram showing the involvement of oxidative stress in Huntington’s disease.
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[120–122, 126]. It is widely regarded as the infectious
agent which can duplicate itself with high conformity by
enlisting endogenous PrPC and that the modiﬁcation
between these isoforms lies strictly in its state of aggregation
and its monomer conformation [120, 127]. Microscopic
examination of the brains of patients with PrDs typically
shows characteristic histopathologic alterations, comprising
of neuronal degeneration, and vacuolation, which gives the
cerebral grey matter a spongiform appearance, and a reac-
tive increase of astroglial cells [125, 128].
Various lines of evidence have recognized markers of oxi-
dative stress in the brains of rodents with prion disease [129,
130] (Figure 6). Immunohistochemical studies in the brains
of scrapie-infected mice have revealed the presence of lipid
oxidation markers, nitrotyrosine (a marker of peroxynitrite
production), and heme-oxygenase-1 (an enzyme leading to
the development of antioxidant molecules), suggesting that
oxidative stress might be one mechanism of neuronal loss
[131, 132]. There are also indications for mitochondrial dam-
age induced by oxidative stress in cells from brains of scrapie-
infected mice and hamsters [133, 134]. Furthermore, a study
by Kim et al. suggested that iron-induced oxidative stress
might be a key mechanism of neuronal loss in scrapie [135].
Unfortunately, there is presently no eﬀective treatment or
disease-modifying therapy for PrDs. The search for treat-
ments is primarily hindered by inadequate understanding
of prion disease pathogenesis. However, identiﬁed drugs
which show some eﬀectiveness in treating prion diseases in
in vitro and in vivo systems include quinacrine and pentosan
polysulfate [136]. These compounds have been used as com-
passionate therapy in CJD patients; however, no therapeutic
value was observed [137, 138]. Other treatment options
attempted for PrDs that have had limited success include
immunotherapy and vaccination [139].
3. General Uses of Rutin
Rutin has been shown to have an extensive array of pharmaco-
logical applications due to its numerous properties including
antioxidant, anti-inﬂammatory, cardiovascular, neuroprotec-
tive, antidiabetic, and anticancer activities [140, 141].
Over the years, various mechanisms have been found to
be responsible for its antioxidant activities in both in vitro
and in vivo models. Firstly, it was reported that its chemical
structure can directly scavenge ROS [142]. Secondly, it
increases the production of GSH and cellular oxidative
defence systems are believed to be upregulated by an
increased expression of numerous antioxidant enzymes such
as CAT and SOD [143–145]. Thirdly, rutin inhibits xan-
thine oxidase which is involved in generating ROS [146].
From the aforementioned, the optimism generated by the
therapeutic potential of rutin in many health conditions
in which oxidative stress is an underlying cause is under-
standable [34, 143, 147, 148]. The rest of this review will
summarize the main ﬁndings of the neuroprotective eﬀects
of rutin in various experimental models of NDs. The var-
ious in vitro and in vivo studies are summarized in
Tables 1 and 2, respectively.
3.1. Studies of Rutin in AD
3.1.1. Toxins Used to Generate Models of AD. Several lines of
evidence indicate that Aβ peptides are the key factors in AD
pathogenesis [149–151]. Aβ peptide, produced from amyloid
precursor protein (APP), is a very important part of amyloid
plaques and has been described to be neurotoxic [152]. It is
hypothesized that an anomaly in the proteolytic processing
of the APP leads to an increase in the generation of Aβ pep-
tides (such as Aβ40–42 and Aβ25–35) which in turn leads to the
buildup of Aβ, a key event in the pathogenesis of AD [153,
154]. Aβ may also induce oxidative stress by causing mito-
chondria dysfunction which results in increased ROS and
decreased levels of antioxidants such as GSH and the activity
of antioxidant enzymes such as SOD, GPx, and CAT [155].
Aβ-induced ROS production is believed to aid Aβ produc-
tion and accumulation, thereby quickening the progression
of AD [68, 156]. Additionally, Aβ induces nitric oxide
(NO) generation by upregulating the expression of nitric
oxide synthase (iNOS) [157, 158] which plays a fundamental
role in the series of events leading to cell death [159].
3.1.2. In Vitro Studies. Aβ accumulation is a key feature of
AD, and rutin has been shown to decrease and reverse
Aβ25–35 ﬁbril formation in vitro indicating that its action
might be connected to their free radical scavenger activity
and might subdue neurotoxicity [153]. Furthermore, in a dif-
ferent study [155], rutin acted as a multifunctional agent by
inhibiting Aβ aggregation and cytotoxicity, preventing mito-
chondrial damage, reducing production of MDA, ROS, NO,
GSSG, iNOS, and proinﬂammatory cytokines, and increasing
CAT, SOD, GSH, and GPx levels. Yu et al. demonstrated the
ability of rutin to inhibit amylin-induced neurocytotoxicity
and enhance antioxidant enzyme activities in the SH-SY5Y
cells [35]. Treatment of human neuroblastoma SH-SY5Y
cells with rutin-loaded nanoparticles conferred protective
eﬀects on Aβ-induced cytotoxicity, decreased levels of NO,
and ROS [160]. In a related activity, rutin modulated the gen-
eration of proinﬂammatory cytokines by reducing TNF-α
and interleukin- (IL-) 1β generation in Aβ40–42-treated BV-
2 cells [155]. Bispo da Silva et al. established that rutin treat-
ment was not toxic to microglial cells and induced a dose-
dependent increase in microglial proliferation, decreasing
the mRNA levels of TNF, IL-1b, IL-6, and iNOS; reduced pro-
duction of IL-6, TNF, and NO; increased production of the
M2 regulatory cytokine IL-10 and arginase; and signiﬁcantly
inhibited the LPS-induced expression of PTGS2, IL-18, and
TGFβ [161].
3.1.3. In Vivo Studies. Several studies have utilized animal
models as a preclinical tool to evaluate the neuroprotective
potential of bioactive compounds such as edaravone and
vitamin D3 in AD [162, 163]. In a study, Xu et al. [164]
showed that following oral administration of rutin at a daily
dose of 100mg/kg for six weeks, rutin attenuated memory
deﬁcits in APPswe/PS1dE9 transgenic mice, reduced oligo-
meric Aβ level as well as downregulated microgliosis and
astrocytosis, and reduced IL-1 and IL-6 levels in the brain.
In an interesting and similar study by Hu et al., intravenous
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administration of Congo red/rutin magnetic nanoparticles
(MNPs) resulted in rescue of memory deﬁcits and ameliora-
tion of neurologic changes in the brains of APPswe/PS1dE9
transgenic mice [160]. Cheng et al. showed that rutin and
exercise enhanced high-fat diet-induced cognitive defects in
mice [165]. Rutin’s ability to alleviate impaired cognition
and memory in Aβ25–35-induced mouse model of AD was
demonstrated by Choi et al. in 2015 [166].
Most recently, Ramalingayya et al. [167] demonstrated
that pretreatment with rutin inhibited doxorubicin- (DOX-)
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Figure 6: Schematic diagram showing the involvement of oxidative stress in prion diseases.
Table 1: Summary of the protective eﬀects of rutin in in vitro models of neurodegeneration.
Toxin used in cellular model Disorder Key ﬁndings Reference
Aβ25–35-treated SH-SY5Y neuroblastoma cells and
Aβ25–35-treated APP695-transfected SH-SY5Y
(APPswe) cells
AD
↓ Aβ ﬁbrils, ↓ β-secretase enzyme (BACE), ↓ ROS, ↑ GSH,
↓lipid peroxidation
[153]
Aβ42-treated SH-SY5Y and BV-2 cells AD
↓ ROS, ↓ NO, ↓ GSSG, ↓ MDA, ↓ iNOS, ↓ MMP, ↑ GSH/
GSSG ratio, ↑ SOD, CAT, and GPx, ↓ TNF-α, ↓ IL-1β
[155]
Amylin-treated SH-SY5Y neuroblastoma cells AD
↑ cell viability, ↓ ROS, ↓ NO, ↓ GSSG, ↓ MDA and ↓ TNF-α
and ↓ IL-1β, ↑ GSH/GSSG ratio, ↑ SOD, ↑ CAT, ↑ GPx, ↓
iNOS
[35]
6-OHDA-treated PC-12 cells PD
↑ cell viability, ↑ 6-OHDA-induced reduction in SOD, CAT,
GPx, and GSH, ↓ lipid peroxidation
[147]
6-OHDA-treated PC-12 cells PD
↑ 6-OHDA-induced reduction in SOD, CAT, GPx, and GSH.
↓ lipid peroxidation, ↓ MDA
[184]
6-OHDA-treated PC-12 cells PD
↓ Park2, ↓ UCHL1, ↓ DJ-1, ↓ Casp3, ↓ Casp7, ↑ TH, ↑ NSF, ↑
Opa1
[185]
Prion peptide-treated HT22 cells PrD ↓ ROS, ↓ NO, ↓ apoptosis, ↓ Fas, ↓ Fas-L [210]
6-OHDA: 6-hydroxydopamine; CAT: catalase; Fas L: Fas ligand; GPx: glutathione peroxidase; GSH: reduced glutathione; GSSG: glutathione disulﬁde; IL-10;
interleukin 10; IL-6: interleukin 6; IL-8: interleukin 8; IL-1β: interleukin 1 beta; iNOS: inducible nitric oxide synthase; MDA: malondialdehyde; MMP:
mitochondrial membrane potential; NSF: N-ethylmaleimide-sensitive factor; Opa1: optic atrophy 1; ROS: reactive oxygen species; SOD: superoxide
dismutase; TH: tyrosine hydroxylase; TNF-α: tumor necrosis factor-α.
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induced ROS generation and increased DOX-induced reduc-
tion of CAT, GSH, and SOD levels inWistar rats. Other ﬁnd-
ings include prevention of DOX-induced cell cycle and
morphological changes, reduction of DOX-induced apopto-
sis, prevention of DOX-induced episodic-likememory deﬁcit,
prevention of rise in TNF-α levels, and reversal of myelosup-
pressive eﬀect of DOX [167]. In a similar AD study by
Ramalingayya et al. [168], rutin dose dependently improved
recognition and discriminative indices in time-induced long-
term as well as scopolamine-induced short-term episodic
memory deﬁcit AD models without disturbing locomotor
activity. Moghbelinejad et al. demonstrated that rutin signiﬁ-
cantly increased extracellular signal-regulated protein kinase
1 (ERK1), cAMP response element-binding protein (CREB),
and brain-derived neurotrophic factor (BDNF) gene expres-
sion in the hippocampus of rats. Studies show that the
mitogen-activated protein kinase (MAPK) cascade that
includes ERK1/2 and CREB is involved in neural plasticity
and survival [169]. Long-lasting changes in synaptic plasticity
and memory are the resultant eﬀects arising from the activa-
tion the MAPK cascade [169]. BDNF aﬀects the survival and
functionofneurons in theCNSand is essential fornormal syn-
aptic connection formation during growth and for learning
and memory in adults [170]. They also found rutin to signiﬁ-
cantly increase memory retrieval while signiﬁcantly lowering
MDA levels in the hippocampus [171].
In a diﬀerent type of AD model, Javed et al. showed that
rutin signiﬁcantly reduced intracerebroventricular streptozo-
tocin- (ICV-STZ-) induced increase in TBARS, poly
ADP-ribosyl polymerase, and nitrite in the hippocampus of
rats. Rutin also signiﬁcantly increased levels of GSH, GPx,
glutathione reductase (GR), and CAT [172]. Furthermore,
rutin also signiﬁcantly improved cognitive deﬁcits, attenuat-
ing STZ-induced inﬂammation by decreasing the expression
of interleukin-8 (IL-8), glial ﬁbrillary acidic protein (GFAP),
cyclooxygenase-2 (COX-2), nuclear factor-κB, inducible
iNOS, and reduced histological abnormalities in the hippo-
campus [172]. In a diﬀerent model of AD using zebraﬁsh,
Table 2: Summary of the protective eﬀects of rutin in in vivo models of neurodegeneration.
Toxin used in animal model Disorder Key ﬁndings Reference
Doxorubicin- (DOX-) treated neuroblastoma cells
(IMR32) and doxorubicin-induced cognitive
dysfunction in Wistar rats
AD
↓ apoptosis, ↓ ROS, ↓ episodic memory deﬁcit, ↓ TNF-α,
↑ DOX-induced reduction of catalase, GSH, and SOD
[167]
Microglial cells obtained from the cortex of Wistar
newborn rats
AD
↓ TNF, ↓ IL-1b, ↓ IL-6, ↓ iNOS, ↑ IL-10, ↑ arginase, ↓ PTGS2,
↓ IL-18, ↓ TGFβ
[161]
∗∗APPswe/PS1dE9 transgenic mice AD
↑ memory, ↑ SOD, ↑ GSH/GSSG ratio, ↓ GSSG, ↓ MDA,
↓IL-1, ↓IL-6
[164]
High-fat diet-induced obese (DIO) cognitively
impaired C57BL/6J mice
AD ↓ cognitive defects [165]
Scopolamine-treated Wistar rats AD ↑ recognition, ↑discriminative indices [168]
Aβ25–35-infused mouse model AD ↓ impaired cognition, ↑ memory, ↓ NO, ↓ lipid peroxidation [166]
Beta-amyloid-induced neurotoxic rats AD ↑ ERK1, ↑ CREB, ↑ BDNF, ↑ memory retrieval, ↓ MDA [171]
Intracerebroventricular streptozotocin- (ICV-STZ-)
infused rats
AD
↓ TBARS, ↓ nitrite level, ↓ poly ADP-ribosyl polymerase,
↑ GSH, ↓ lipid peroxidation, ↓ cognitive deﬁcits, ↓ COX-2,
↓ GFAP, ↓ IL-8, ↓ iNOS, ↓ NF-κB
[172]
Scopolamine-induced zebraﬁsh AD ↓ amnesia [173]
Intrastriatal injection of 6-OHDA in rats PD
↓ 6-OHDA-induced increase in rotations, ↓ deﬁcits in
locomotor activity, ↓ motor coordination, ↑ antioxidant
levels, ↑ DA, ↑ dopaminergic D2 receptors
[78]
Haloperidol-treated rats PD
↓ catalepsy, ↓ akinesia, ↑ locomotor activity, ↑ GSH, ↑ SOD,
↓ TBARS
[77]
3-Nitropropionic (3-NP) acid-treated rats HD
Improved 3-NP-induced behavioral alterations; restored
activities of mitochondrial complex enzymes
[199]
3-Nitropropionic (3-NP) acid-treated rats HD Restored biochemical, behavioral, and cellular alterations [200]
3-Nitropropionic (3-NP) acid-treated rats HD
↑ body weight, ↑ locomotor activities, ↑ memory,
↑ antioxidant levels, ↓ lipid peroxides, ↓ nitrite, ↓ GFAP,
↓ AchE
[201]
∗∗Rutin loaded magnetic nanoparticles were used in this experiment; 6-OHDA: 6-hydroxydopamine; AchE: acetylcholine esterase; BDNF: brain-derived
neurotrophic factor; CAT: catalase; CREB: cAMP response element binding protein; DA: dopamine; doxorubicin: DOX; ERK1: extracellular signal-regulated
kinase 1; GFAP: glial ﬁbrillary acidic protein; GPx: glutathione peroxidase; GSH: reduced glutathione; GSSG: glutathione disulﬁde; IL-10: interleukin 10;
IL-6: interleukin 6; IL-8: interleukin 8; IL-1b: interleukin 1 beta; iNOS: inducible nitric oxide synthase; MDA: malondialdehyde; MMP: mitochondrial
membrane potential; NF-κB: nuclear factor-kappaB; NSF: N-ethylmaleimide-sensitive factor; PTGS2: prostaglandin-endoperoxide synthase 2; ROS: reactive
oxygen species; SOD: superoxide dismutase; TBARS: thiobarbituric acid reactive substances; TGFβ: transforming growth factor beta; TH: tyrosine
hydroxylase; TNF-α: tumor necrosis factor-α.
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Richetti et al. were able to show that rutin did not aﬀect zebra-
ﬁsh general locomotor activity and prevented scopolamine-
induced amnesia [173].
The various studies highlighted in this section demon-
strates the neuroprotective capability of rutin in ameliorating
the adverse eﬀects of neurodegeneration as well as cognitive
impairments associated with AD in various animal models.
3.2. Studies of Rutin in PD
3.2.1. Toxins Used to Generate Models of PD. Over the years,
neurotoxins used to induce dopaminergic neurodegeneration
include 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), 1,1-dimethyl-4,4-bipyri-
dinium (paraquat) and rotenone [174, 175]. Seemingly, all of
these toxins provoke the formation of ROS. 6-OHDA is
known to be taken up by dopaminergic neurons through the
dopamine transporter [174, 176]. In the neurons, oxidized
molecules of 6-OHDA produces free radicals that hinders
mitochondrial complex I and produces •O−2 and
•OH which
becomes toxic to dopaminergic neurons and induces micro-
glial activation. Rotenone andMPTP are known for their ease
of use in animals and their similar ability to potently inhibit
complex I. After its systemic administration, MPTP swiftly
crosses the blood brain barrier [175].
Once in the brain, MPTP is converted in the astrocytes by
monoamine oxidaseB (MAO-B) to 1-methyl-4-phenylpyridi-
nium (MPP+) and is thereafter released into the extracellular
space [175, 177, 178]. Once inside dopaminergic neurons,
MPP+ accumulates in mitochondria and impairs mitochon-
drial respiration by impeding complex I in the electron trans-
port chain, which induces the production of ROS [177, 179].
Rotenone is also very lipophilic and is circulated evenly
throughout the brain after crossing the BBB [174, 180]. Para-
quat, an herbicide, has a very close structural similarity to
MPP+ and has been proposed to be a risk factor for PD
[181]. A neurobehavioral syndrome characterized by reduced
ambulatory activity, a decline in striatal dopamine nerve ter-
minal density, and a signiﬁcant decrease in substantia nigra
dopaminergic neurons have all been associated and linked to
eﬀects fromsystemic administrationof paraquat [182]. Exper-
imental evidence show that paraquat crosses the BBB to cause
damage to the dopamine neurons in the substantia nigra, like
MPP+ [182]. In addition, sustained exposure to paraquat
results in a marked accrual of α-synuclein-like aggregates in
neurons of the substantia nigra pars compacta in mice [183].
3.2.2. In Vitro Studies. PD has been modelled in vitro through
the speciﬁc neurotoxic eﬀect of the 6-OHDA on dopaminer-
gic neurons. Neurotoxicity triggered by 6-OHDA was atten-
uated by rutin treatment in PC12 cells where a signiﬁcant
dose-dependent cytoprotective activity was detected in
rutin-pretreated cells [147]. Rutin activated antioxidant
enzymes including SOD, CAT, GPx, and GSH when com-
pared to cells incubated with 6-OHDA alone in conjunction
with a signiﬁcantly reduced lipid peroxidation activity [147,
184]. In 2015, Magalingam et al. reported that pretreatment
with rutin in PC12 cells downregulated the mRNA expres-
sion of PD-linked genes (PARK2, UCHL1, and DJ-1) and
proapoptotic (Casp3 and Casp7) genes which were upregu-
lated in the 6-OHDA-treated PC12 cells [185]. The study
showed that rutin upregulated the TH gene which is essential
in dopamine biosynthesis and further upregulated the ion
transport and antiapoptotic genes (NSF and Opa1) [185].
In a diﬀerent model of PD, rutin pretreatment pre-
vented rotenone-induced loss of SH-SY5Y cells, inhibited
rotenone-induced ROS formation, and suppressed eleva-
tion of calcium [34]. Rutin attenuated rotenone-induced
reduction of mitochondrial membrane potential and acti-
vation of the JNK and p38 MAPK pathways, reversed
changes of Bcl-2 and Bax levels, and inhibited apoptosis
and caspase-9/3 activation [34].
3.2.3. In Vivo Studies. In one of the very few and earliest stud-
ies documenting the neuroprotective eﬀects of rutin in in vivo
models, oral administration of rutin signiﬁcantly protected
against 6-OHDA-induced increase in rotations, deﬁcits in
locomotor activity and motor coordination in male Wistar
rats [78]. Immunohistochemical and histopathological ﬁnd-
ings in the substantia nigra showed that rutin protected neu-
rons from toxic eﬀects of 6-OHDA [78]. In a diﬀerent model
of PD, Sharma et al. [77] showed that rutin played an impor-
tant role in attenuating behavioral, biochemical, and histo-
logical parameters after haloperidol administration in rats
and further conﬁrmed the protective eﬀects of rutin.
These in vivo and in vitro studies exhibit the potential of
rutin as a neuroprotector and suggest a role for this com-
pound in the prevention and reversal of degenerative diseases
such as PD.
3.3. Studies of Rutin in HD
3.3.1. Toxins Used to Generate Models of HD. Animalmodels
of HD have provided understanding into disease pathology,
and previous studies of HD used toxin-induced models to
study excitotoxicity-induced cell death and mitochondrial
impairment, both mechanisms of HD degeneration. These
models, based on quinolinic acid (QA) and 3-nitropropionic
acid (3-NP), are still often used in HD studies [186]. QA is
experimentally administered straight to the striatum because
it is incapable of crossing the BBB [187]. Its key features
include striatal neurodegeneration in rats [188, 189], mice
[190], and primates [191, 192] in a strikingly similar pattern
to that seen in human HD. Its advantages as a HD model
includes its ease of use inmore complex animals, its inﬂuences
on cognitive function, numerous resemblances between
pathology observed in theHDbrain, and itsmode of cell death
that mimics the mechanism of neuronal death seen in HD
brains [193–195]. 3-NP is known to irreversibly inhibit the
mitochondrial enzyme succinate dehydrogenase [196, 197].
Its major advantage is that it mimics cell death seen in the
HD brain through a combination of apoptosis and necrosis
[186]. Instantly after administration of 3-NP, there is a surge
of necrotic cell death followed by gradual apoptosis [198].
3-NP crosses the blood-brain barrier and can be administered
systemically to mice, rats, and nonhuman primates [186].
3.3.2. In Vivo Studies. In a pioneering work on HD with rutin
in 3-NP-treated rats, Suganya and Sumathi reported that oral
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administration of rutin (25mg/kg and 50mg/kg) signiﬁ-
cantly decreased protein oxidation and improved endoge-
nous antioxidant defence system. Furthermore, rutin
improved 3-NP-induced behavioral alterations and restored
the activities of mitochondrial complex enzymes (I, II, IV,
and V) when compared to the 3-NP-induced group [199].
In 2016, Suganya and Sumathi again reported that oral
administration of rutin (25mg/kg body weight) to Wistar
rats increased the levels of nonenzymatic antioxidants
(vitamin C and E) when compared to a reduction in the
3-NP-induced group. In addition, rutin protected against
3-NP-induced reduction in motor activities, muscle coor-
dination, and activities of adenosine triphosphatases
(ATPases) [200].
Most recently, Suganya and Sumathi showed that rutin
restored 3-NP-induced reduction of body weight, locomotor
activities, memory, and antioxidants levels. They further
stated that rutin ameliorated 3-NP-induced striatal damage
by reducing levels of lipid peroxides, nitrite, GFAP, and activ-
ity of acetylcholine esterase [201].
Although these few in vivo studies oﬀer concrete evidence
for the therapeutic potential of rutin, there exists a critical
need to further elucidate and provide more evidence for the
therapeutic potential of rutin in in vitro models of HD.
3.4. Studies of Rutin in PrD
3.4.1. Toxins Used to Generate Models of PrD. The prion pro-
tein peptide 106–126 (PrP (106–126)) has frequently been
used as a model system to study prion-induced neurodegen-
eration [202, 203]. This peptide induces neurotoxicity in
neuronal cells owing to its amyloidogenic properties both
in vivo and in vitro [204]. One of the major advantages
of PrP (106–126) is that it is comparable to PrPSc in
numerous respects and at the same time is more soluble
and easy to deploy for cell culture experiments [205].
PrP (106–126) is rich in β-sheet structure, increases the
membrane microviscosity of neurons and astrocytes [206],
and forms aggregates that are proteinase K-resistant and
detergent-insoluble [204, 207, 208]. PrP (106–126) weakens
liposomes and induces liposome fusion [209].
3.4.2. In Vitro Studies. In a pioneering study [210], the
authors studied the neurotoxicity of PrP (106–126) in the
HT22 hippocampal cell line and assessed the neuronal pro-
tection provided by rutin against the toxic eﬀects of PrP
(106–126). Rutin treatment blocked PrP- (106–126-) medi-
ated increases in ROS production and NO release and
delayed the decrease of neurotrophic factors that resulted
from PrP accumulation. In addition, rutin mitigated PrP-
(106–126-) associated mitochondrial apoptotic events by
hindering mitochondrial permeability transition and
caspase-3 activity and blocking expression of the apoptotic
signals (Bax and PARP) in conjunction with a signiﬁcantly
reduced expression of the death receptor Fas and its ligand
Fas-L [210].
There are currently no in vivo studies on the therapeutic
potential of rutin in PrP models. Consequently, there is a dire
need to further elucidate and provide more evidence for the
therapeutic potential of rutin in more in vitro and in vivo
models of PrD.
4. Future Perspectives and Conclusion
Numerous in vitro (Table 1) and in vivo (Table 2) studies
have demonstrated the ability of rutin to ameliorate various
neurodegenerative processes that trigger AD, PD, HD, and
PrDs. The ability of rutin to exert its neuroprotective eﬀects
in diﬀerent models of NDs could be ascribed to its antioxi-
dant as well as antiapoptotic and anti-inﬂammatory activi-
ties. In addition, rutin’s activation of BDNF and the MAPK
cascade (ERK1/2 and CREB) signiﬁes its involvement in plas-
ticity and survival of neurons in the CNS.
The benchmark for authenticating rutin’s neuroprotec-
tive properties is clinical trials in humans. A few clinical trials
have been conducted to examine the eﬀect of a compound
from the rutin family, O-(β-hydroxyethyl)-rutosides (HRs)
in venous disease patients with diabetes treated for a pro-
longed period of time [211]. HRs is obtained by substituting
rutin hydroxyl groups with O-β-hydroxyethyl groups.
Human clinical trials with rutin (in the form of HRs) have
shown that it is safe and well tolerated [211]. The lack of clin-
ical trials exploring the eﬃcacy of rutin in NDs is of concern.
This may be due to lack of suﬃcient data on animal models
in the various NDs.
As a ﬂavonol among similar ﬂavonoids, rutin’s low bio-
availability [212] owing to high metabolism, poor absorption,
and rapid excretion generally makes its prospective use as a
therapeutic agent restricted. Further studies to improve its
bioavailability and investigations into its protective activities
in more models of NDs (most especially PrDs and motor
neuron disease) would provide a solid foundation for its
use in clinical trials. Rutin’s ability to oﬀer neuroprotection
against pathological insult oﬀers hope in its utilization and
development as a safe and eﬀective neurotherapeutic agent.
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